7:30 am Check-In & Coffee
8:30 am Chair’s Opening Remarks
Comparing CAR-T & Emerging Modalities to Guide Modality Selection & Refine Therapeutic Strategy
8:40 am Industry Leaders Fireside Chat: Evaluating CAR-T in Comparison to Emerging Modalities to Refine Autoimmune Therapies Through Strategic Modality Selection
Synopsis
- Explore the efficacy of differing modalities to identify opportunities where we can learn from other modalities
- Compare modalities in their affinity for targeting autoreactive cells to minimize side-effects and enhance safety
- Identify autoimmune indications where CD-19-CARs are suboptimal to spotlight opportunities for alternative therapeutic modalities
9:30 am Keynote Presentation: Showcasing Cabaletta Bio’s Rese-cel Data & Industry Implications to Progress CAR-T in Autoimmunity
Synopsis
- Explore rese-cel, a CAR-T cell therapy, combating autoimmune diseases to provide insight into the future of autoimmune cell therapies
- Discuss how translational and mechanistic insights accelerated the design and development of rese-cel in autoimmunity
- Evaluate the depth of peripheral and tissue-level target cell depletion with rese-cel in patients with autoimmune disease
10:00 am Morning Break & Speed Networking
Synopsis
As this community reunites, this session will provide valuable networking time with your peers, and new faces in the autoimmune space, enabling you to forge new and lasting connections.
Preclinical & Translational
Investigating Next-Generation Antibody Targeting Strategies to Enhance Precision & Efficacy
11:00 am Expanding CAR-T Targets Beyond CD-19 to Enhance Treatment Efficacy Across Autoimmune Diseases
Synopsis
- Evaluate CD-19’s strengths and limitations as the anchor target for CAR-T treatment of autoimmune diseases
- Explore novel targets to broaden the spectrum and complexity of treatable autoimmune diseases
- Evaluate available targeting options to pinpoint optimal targets for varying autoimmune and autoinflammatory diseases
11:30 am Evaluating Opportunities to Engineer the Autoimmune Microenvironment to Sustain Target Engagement
Synopsis
- Dissect microenvironmental factors that influence target accessibility and therapeutic cell performance
- Tackle challenges in tonic signaling to secure ligand and graft antibody attachment and maintain therapeutic potency
- Discuss strategies to generate a propitious microenvironment that enhances homing to receptors and sustains therapeutic effects
12:00 pm Reserved for Thermo Fisher Scientific
Clinical
Exploring Immune Cell Targeting to Enhance Treatment Efficacy & Durability
11:00 am Optimizing Immune Cell Target Selection to Deliver Effective Autoimmune Therapies
Synopsis
- Evaluate which immune cell targets have demonstrated the greatest therapeutic benefits to guide treatment decisions
- Understand patient tolerance to targeting alternative immune cells to optimize safety and efficacy
- Leverage insights from Nkarta Therapeutics’ NK cell-based Non-Hodgkins Lymphoma therapy to predict autoimmune success
11:30 am Leveraging NK Therapies to Advance Autoimmune Cell Therapy Safety
Synopsis
- Highlight the rationale and potential advantages of utilizing a non-genetically modified NK cell therapy in combination with monoclonal antibodies in autoimmune diseases
- Explore clinical data demonstrating that NK cell therapies can drive deep B-cell depletion in autoimmune disease while avoiding side effects inherent in CAR-T and TCE therapies
- Highlight a framework for selecting indications for different cell therapies based on their potential target product profile
12:00 pm Reserved for Promega Corporation
12:10 pm Lunch & Networking Break
Exploring Innovations in B-Cell Depletion & Beyond to Advance Immune Modulation
1:10 pm Exploring Autologous CD-19 CAR-Tregs for Rheumatology to Advance Treatment Development for Unmet Diseases
Synopsis
- Explore the role of the immune system in rheumatoid scleroderma
- Hear preclinical evidence from Quell Therapeutics on their novel therapy targeting rheumatoid scleroderma
1:40 pm Panel Discussion: Comparing Immune Cell Depletion & Immune Tolerance Therapies to Accelerate Safer, Efficacious Therapies
Synopsis
- Expand therapeutic approaches beyond B-cell depletion
- Highlight safety challenges with depletion in comparison to tolerance with Tregs
- Explore the long-term biological effects of B-cell depletion and immune reprogramming therapies
Optimizing Immune Cell Depletion Strategies to Enhance Safety, Persistence & Long-Term Remission in Autoimmune Therapies
1:10 pm Advancing T-Cell-Targeted Therapies for Autoimmune Diseases to Unlock More Precise & Durable Treatment Options
Synopsis
- Explore T-cell targeting strategies to combat SLE and improve therapeutic outcomes
- Examining Novartis’ srSLE CAR-T data to uncover insights into novel CAR-T approaches to address unmet medical needs
- Highlight Novartis’ novel CAR-T manufacturing platform (T-Charge) to evaluate its impact on enhancing T-cell targeted treatments for autoimmune diseases
1:40 pm Panel Discussion: Utilizing Biomarkers to Sustain Durable Responses in Autoimmune Therapies
Synopsis
- Identify the capacity of biomarkers to predict therapeutic responses
- Harness specific biomarkers to effectively identify patient response, manage patient safety and enhance patient selection
- Explore the use of biomarkers to determine optimal timing for re-dosing and sustaining efficacy
2:30 pm Afternoon Break & Poster Session
Synopsis
This is your opportunity to contribute to the conversation and share your cutting-edge research with this community, while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.
Delving into Cell Therapy Innovations to Explore the Future of Autoimmune Cell Therapies
3:30 pm Demonstrating Durable Remission in Lupus with iCell Gene Therapeutics’ Dual-Target, Armored CAR-T Therapy
Synopsis
- Introducing iCell Gene Therapeutics’ ICG318 CD-19—BCMA/IL-15 compound CAR-T
- Evaluate the synergistic impact of combined B-cell and plasma cell depletion in enhancing durability of response
- Highlight iCell Gene Therapeutics’ 5+ year long-term follow-up data, to define what therapeutic durability looks like in lupus patients
4:00 pm Keynote Presentation: Reserved for Umoja Biopharma
4:30 pm Advancing In Vivo RNA Therapies Towards Clinical in B-Cell-Mediated Autoimmune Diseases
Synopsis
- Share data highlighting the benefits of in vivo therapies in autoimmune diseases
- Share NHP preclinical data highlighting the benefits of in vivo RNA therapy
- Highlight the development of in vivo CAR-T therapy for the clinic